MTFMT

Across TCGA pan-cancer cohorts, MTFMT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTFMT data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTFMT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTFMT expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MTFMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.447	0.852	.005	10	view →
CCRCC	DFS	Quartile	III,IV	0.078	0.805	.017	5	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.686	.033	2	view →
HNSC	DFS	Median	All	0.984	0.918	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTFMT–PDAC (DFS)

Open the PDAC breakdown →